Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …

PURPOSE No combined immunotherapy and antiangiogenic therapy have been
investigated in exclusively programmed death-ligand 1 (PD-L1)–positive advanced cervical …

The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

Background The immune system interacts with cancer cells in various intricate ways that can
protect the individual from overproliferation of cancer cells; however, these interactions can …

Purpose: Anlotinib has achieved good results in clinical trials of a variety of cancers.
However, the effects of anlotinib on the tumor microenvironment (TME) and systemic …

Favorable clinical evidence suggests that the next trend in new treatments for advanced non-
small cell lung cancer (NSCLC) will be combination therapies. However, inevitable …